Pioneering innovative products to meet complex patient challenges.
At Indivior, we are committed to pioneering innovative and accessible medicines to help patients suffering from substance use and mental health illnesses.
Our people, culture, expertise and patient understanding, coupled with our innovative technology and stakeholder relationships, uniquely position us to help address patients’ unmet needs around the world.
Our portfolio of products is available in more than 40 countries. Within these countries, product availability may differ in terms of dosage form, strength and indication.
Country specific product and prescribing information available upon request.
U.S. Product Portfolio:
Current U.S. Products:
(buprenorphine extended-release) injection for subcutaneous use (CIII)
(buprenorphine and naloxone) Sublingual Film (CIII)
(risperidone) for extended-release injectable suspension
|U.S. Prescribing Information, including BOXED WARNING|
Indivior sells legacy products such as Temgesic, Burpex and Buprenex in various countries outside the United States.
SUBLOCADETM (BUPRENORPHINE EXTENDED-RELEASE) INJECTION IMPORTANT SAFETY INFORMATION WITH BOXED WARNING